Lacripep is under clinical development by TearSolutions and currently in Phase II for Sicca Syndrome (Sjogren). According to GlobalData, Phase II drugs for Sicca Syndrome (Sjogren) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Lacripep LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lacripep overview
Lacripep is under development for the treatment of primary Sjogren’s syndrome dry eye. It is administered by ophthalmic route and formulated in the form of solution (drops). The drug candidate is a synthetic fragment of lacritin.
TearSolutions overview
TearSolutions is a biopharmaceutical company. It focuses on discovery and development of topical drugs to treat dry eye syndrome. TearSolutions is investigating Lacripep, a topical synthetic tear protein fragment of lacritin that restores tearing and treat dry eye associated with primary sjogren’s syndrome. The company is a spin-out from the University of Virginia. TearSolutions is headquartered in Charlottesville, Virginia, the US .
For a complete picture of Lacripep’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
